The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases
J. Nagelschmitz, D. Kaufel, S. Stephan, F. von Nussbaum, V. Li, M. Delbeck, K. Lustig, T. Bandel, H. Watz (Wuppertal, Grosshansdorf, Germany)
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Session: New drugs for asthma, COPD and pulmonary fibrosis
Session type: Oral Presentation
Number: 3416
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Nagelschmitz, D. Kaufel, S. Stephan, F. von Nussbaum, V. Li, M. Delbeck, K. Lustig, T. Bandel, H. Watz (Wuppertal, Grosshansdorf, Germany). The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases. Eur Respir J 2014; 44: Suppl. 58, 3416
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The novel elastase inhibitor BAY 85-8501: First-in-man study to evaluate safety, tolerability and pharmacokinetics in healthy male subjects Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016
A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014
Safety and tolerability of the NE inhibitor BAY 85-8501 in patients with non-CF bronchiectasis Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
LATE-BREAKING ABSTRACT: Anti-inflammatory effect of RP6557, a dual PI3K d/? inhibitor, in glucocorticoid insensitive human neutrophils from chronic obstructive pulmonary disease patients Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014